Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Clinical trial NCT00744536 · COMPLETED

Trial details

NCT number: NCT00744536
Sponsor: Sunnybrook Health Sciences Centre
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Angiogenesis

Start date: 2008-01-01
Primary completion: 2012-01-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.